3 Rock-Solid Dividend Stocks to Buy and Hold for Decades

The article highlights three dividend-growth names—AbbVie (ABBV), Enbridge (ENB), and Coca-Cola (KO)—with yields of ~2.8%, ~5.1%, and ~2.5%, respectively. AbbVie boosted its quarterly dividend 33% over five years (~5.9% CAGR) while growing nearly 9% YoY last year; Enbridge has increased dividends for 31 straight years (~9% CAGR) and met 2025 guidance for the 20th consecutive year; Coca-Cola increased its dividend for 64 consecutive years, with the latest raise up 4% and FY net income of $13.1B on $47.9B revenue (27% margin). Overall, it frames the group as steady long-term income/cashflow compounders, with limited near-term market-moving catalysts.

Analysis

This reads less like a catalyst and more like a positioning reminder: the market pays up for “safe yield” only when the payout is paired with either visible earnings compounding or a falling-rate backdrop. ABBV is the only name here with enough idiosyncratic growth to defend a premium multiple; KO is a low-volatility compounder, but its dividend story mostly protects downside rather than creating upside. ENB is the most rate-sensitive of the three and will trade more like a duration proxy than an energy beneficiary if long-end yields stay sticky.

Second-order, the real flow is not into these singles so much as into dividend baskets and factor funds such as XLP, VIG, and NOBL if investors rotate out of cash. That said, these names can become crowded “bond proxies,” which caps upside once the market has already priced in safety. ENB also competes directly with utilities and REITs for income capital, so it is vulnerable to any further bond selloff; ABBV’s cleaner cash conversion makes it the best relative shelter if healthcare de-rates but risk assets remain choppy.

Contrarian view: the consensus is conflating dividend reliability with alpha. In a soft-landing/risk-on tape, these will likely lag cyclicals and AI beneficiaries; in a hard landing, payout safety helps but multiple compression can still dominate. The best setup is not chasing the article’s basket, but buying ABBV on weakness and treating ENB as a rates call rather than an energy call.

Key Decisions for Investors

• Long ABBV vs short XBI/IBB for 1-3 months: best blend of earnings visibility and capital return; thesis breaks if Skyrizi/Rinvoq growth decelerates or reimbursement pressure emerges.
• Avoid initiating ENB at current levels unless long-end yields roll over; otherwise it is dead money and likely underperforms utility/dividend proxies if 10Y yields stay elevated.
• Short ENB vs long XLE as a relative-value pair for 1-3 months if rates remain sticky and crude is range-bound; the pipeline name is the more fragile duration trade.
• Use KO as a defensive core holding only on pullbacks, not as a momentum trade; upside is limited unless staples rerate or FX becomes a tailwind.
• If rates break materially lower, rotate into dividend ETFs (VIG/XLP) rather than chasing the single names; the factor flow is likely larger than any idiosyncratic rerating.